Acceleron Pharma Inc.
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It is developing sotatercept to treat patients with chronic kidney disease, including mineral-bone disorder, vascular calcification, and anemia; and luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia. The company is also developing dalantercept therapeutic candidate to treat renal cell carcinoma; and ACE-083 to promote muscle growth and function in specific treated muscles. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.